Brought to you by 
Ipsen teams up with Harvard Medical School for botulinum toxins for neurological conditions
06 Apr 2015
Executive Summary
Ipsen has teamed up with Harvard University's Harvard Medical School on the research and development of engineered botulinum toxins (BTs) for neurological diseases.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ipsen teams up with Harvard Medical School for botulinum toxins for neurological conditions
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice